A meta-analysis of 17 trials including over 9,000 toddlers found no evidence that parent-focused early childhood obesity prevention programs have an impact on young children's BMI.

Authors say their findings underscore the need to re-think current behavioural approaches to prevent obesity in early childhood and stress the need for broader, coordinated and resourced public health action.

Existing approaches to parent-focused behavioural programs delivered up to 12 months of age which aim to combat childhood obesity are insufficient to improve body mass index (BMI) at approximately two years of age, according to the largest study to date on the topic published in The Lancet.

Death rates from diseases such as cancer, heart disease and stroke declined in four out of five countries around the world in the decade leading up to the COVID-19 pandemic, but progress has slowed compared to the previous decade.

Although Latinos and Hispanics are at elevated risk for Alzheimer’s disease and account for almost half of Los Angeles County’s population, a recent UCLA Health study finds that accessible digital resources for these communities remain in short supply since the COVID-19 pandemic.

The rapid rise of adults taking GLP-1RA medications (e.g., Wegovy, Ozempic, Mounjaro) in the U.S. (16 million and counting) and around the world has been accompanied by a slew of the drugs’ proclaimed health benefits. Weight loss is a common (and extremely popular) side effect, making GLP-1RAs some of the most exciting weapons in the arsenal for battling the obesity epidemic. Loss of unhealthy visceral fat and improved blood sugar control are just two of the downstream effects of this weight loss, which, in turn, promise their own health benefits.

But what do we really know about the long-term impacts of GLP-1RA medications? Researchers caution us not to get ahead of ourselves when it comes to the logical, though still theoretical, possibilities of how these drugs may influence related health conditions such as cancer.